Biosino Bio-Technology and Science (HKSE:08247) LT-Debt-to-Total-Asset: 0.03 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:08247 Biosino Bio-Technology and Science Inc HKSE:08247
37 GF Score
Price HK$3.17
GF Value HK$0.44
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Biosino Bio-Technology and Science LT-Debt-to-Total-Asset?

Biosino Bio-Technology and Science HKSE:08247 -2.62% 37 LT-Debt-to-Total-Asset is 0.03 as of Dec. 2025. GuruFocus rates HKSE:08247 with a GF Score™ of 37/100 and a GF Value™ of HK$0.44 (Significantly Overvalued). The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Biosino Bio-Technology and Science's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.03.

Biosino Bio-Technology and Science's long-term debt to total assets ratio increased from Dec. 2024 (0.01) to Dec. 2025 (0.03). It may suggest that Biosino Bio-Technology and Science is progressively becoming more dependent on debt to grow their business.

Biosino Bio-Technology and Science  (HKSE:08247) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Biosino Bio-Technology and Science LT-Debt-to-Total-Asset Related Terms

Biosino Bio-Technology and Science LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Biosino Bio-Technology and Science's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biosino Bio-Technology and Science LT-Debt-to-Total-Asset Chart

Biosino Bio-Technology and Science Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.03 0.01 0.01 0.03

Biosino Bio-Technology and Science Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.03
HKSE:08247
37GF Score
Biosino Bio-Technology and Science Inc HKSE:08247
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biosino Bio-Technology and Science LT-Debt-to-Total-Asset Calculation

Biosino Bio-Technology and Science's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=11.629/449.76
=0.03

Biosino Bio-Technology and Science's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=11.629/449.76
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.03 mean?
Biosino Bio-Technology and Science (HKSE:08247) has a LT-Debt-to-Total-Asset of 0.03 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Biosino Bio-Technology and Science and its competitors.
Is Biosino Bio-Technology and Science's LT-Debt-to-Total-Asset too high?
Biosino Bio-Technology and Science's current LT-Debt-to-Total-Asset is 0.03. Overall, Biosino Bio-Technology and Science has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biosino Bio-Technology and Science's LT-Debt-to-Total-Asset compare to TMO and DHR?
Biosino Bio-Technology and Science's LT-Debt-to-Total-Asset of 0.03 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Diagnostics & Research company?
A good LT-Debt-to-Total-Asset depends on the Medical Diagnostics & Research industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Biosino Bio-Technology and Science and its competitors. Biosino Bio-Technology and Science's current LT-Debt-to-Total-Asset is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosino Bio-Technology and Science stock overvalued right now?
Based on GuruFocus' analysis, Biosino Bio-Technology and Science (HKSE:08247) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.44, compared to a current price of HK$3.17 — trading 619.3% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.03. Biosino Bio-Technology and Science's overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Biosino Bio-Technology and Science (HKSE:08247), the current LT-Debt-to-Total-Asset is 0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biosino Bio-Technology and Science (HKSE:08247) Overvalued in 2026?

Based on GuruFocus' analysis, Biosino Bio-Technology and Science stock appears to be overvalued. The current stock price of HK$3.17 is trading 619.3% above its estimated GF Value™ of HK$0.44. GuruFocus considers Biosino Bio-Technology and Science to be Significantly Overvalued.

Key valuation signals for HKSE:08247:

  • LT-Debt-to-Total-Asset: 0.03
  • GF Value™: HK$0.44 vs. price of HK$3.17 (619.3% above fair value)
  • GF Score™: 37/100 with 6 warning signs

No single metric tells the full story. See the HKSE:08247 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biosino Bio-Technology and Science Business Description

Address No. 27 Chaoqian Road, Science and Technology Industrial Park, Changping District, Beijing, CHN, 102200
Biosino Bio-Technology and Science Inc is engaged in the manufacture, sale, and distribution of IVD reagent products. The company operates in a single segment, the in-vitro diagnostic products segment, which manufactures, sells, and distributes a variety of mono/double diagnostic products. Geographically, it generates the majority of the revenue from Mainland China.
37GF Score

Get the complete analysis for HKSE:08247

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.17
Price
HK$0.44
GF Value